ENDPOINTS

Zealand partners with Roche on petrelintide in a deal w...

Zealand Pharma has finally found a partner. Zealand said Wednesday it will b...

Zealand partners with Roche on petrelintide in a deal w...

Zealand Pharma has finally found a partner. Zealand said Wednesday it will b...

FDA review departments largely spared from Musk-led cuts

Since President Trump took office, Elon Musk's Department of Government Efficien...

Merck dodges ‘failure to warn’ claims in federal Gardas...

Merck convinced a federal judge to toss claims alleging that it failed to proper...

Gilead plans to skip from Phase 1 to Phase 3 with once-...

Gilead said two experimental once-a-year versions of its HIV prevention shot len...

Walgreens turns on dark mode

After months of reports that Walgreens was looking to go private, the retail pha...

Corrected: Merck opens billion-dollar US facility to ma...

Merck has opened a new manufacturing plant in Durham, NC, which will make HPV va...

Mineralys aims to raise $250M; Coherus discloses layoffs

Plus, news about BioNTech, Roche, Boehringer Ingelheim, CervoMed, Genmab, Inozym...

Endo sells international business for $84M

Endo is selling its international pharmaceuticals business to Knight Therapeutic...

Merck opens billion-dollar facility to make bladder can...

Merck has opened a new vaccine manufacturing plant at its existing site in Durha...

Define Ventures hires former Aetion CEO Carolyn Magill

Former Aetion CEO Carolyn Magill has joined digital health venture firm Define V...

Arvinas and Pfizer’s PROTAC vepdegestrant works in subs...

Arvinas and Pfizer’s targeted protein degrader has not managed to distinguish it...

Bristol Myers buys out cell therapy partner 2seventy bio

Bristol Myers Squibb will acquire its CAR-T cell therapy collaborator 2seventy b...

Virtual physical therapy startup Hinge Health files to ...

Virtual physical therapy startup Hinge Health on Monday filed to go public, snap...

New Flagship startup aims to trailblaze ‘AI science fac...

A new Flagship Pioneering startup has emerged with $200 million and a team of ex...

BioNTech's shares dip after posting lukewarm revenue gu...

BioNTech has forecast lackluster sales for 2025 despite ending last year on a re...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.